Emvenio Research

What Emvenio Research does

Emvenio Research, Inc., operating commercially as EmVenio Clinical Research, is a US-domiciled provider of decentralized clinical trial (DCT) services headquartered in Denver, Colorado, with a European base in Losser, the Netherlands. The company delivers three integrated service lines—Mobile Visits (licensed clinicians conducting protocol-trained visits at patients' homes, workplaces, or other locations), a Site Network of hospital-embedded Research Centers and Community Research Sites, and a Patient Navigator concierge service covering travel, lodging, and reimbursement—underpinned by its ARC(H) platform (Access, Reach, Community, Human-Centered Research). It sells these services primarily to pharmaceutical sponsors and contract research organizations via enterprise field sales, RFP-driven study contracts, and an event-led commercial motion across more than 90 countries. EmVenio traces its operational roots to PCM Trials, founded in 2008; PCM Trials acquired both EmVenio Research Inc. and Clinical Trial Service in 2024, and the three entities were rebranded as EmVenio Clinical Research in August 2025. EmVenio is a division of Professional Case Management (PCM), a privately held company founded in 1986 with approximately 5,000 employees worldwide, and operates US, UK, Canadian, and European legal entities under wholly owned subsidiaries including EmVenio Clinical Research, LLC and EmVenio Clinical Research Europe, B.V. Revenue is generated through professional services contracts—study-level per-visit fees, site activation fees, and managed service agreements—while patients participate free of charge, often with time-and-travel compensation.

Name

Emvenio Research

Legal name

Emvenio Research, Inc.

Website

https://emvenio.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

EmVenio Clinical Research provides decentralized clinical trial services—mobile visits, a hospital- and community-embedded site network, and patient navigation—to pharmaceutical sponsors and CROs across 90+ countries. It operates as a division of Professional Case Management, supporting more than 200 sponsors and 800 studies since 2008.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Home Health Care Services (621610)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Decentralized & Hybrid Trial Site Services (Home Health/Nursing) (HLAGACAH), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Decentralized clinical trials
• Clinical research services
• Mobile research visits
• Patient recruitment services
• Site network management

Headquarters

HQ city

Denver

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

1. Clinical Research Services: Contract research services provided to pharmaceutical sponsors and CROs including mobile visits, site network management, patient navigation, and decentralized trial execution. Revenue generated through study contracts based on per-visit fees, site activation fees, and service agreements.
2. Site Network Operations: Management of research centers and community research sites providing clinical trial infrastructure and patient recruitment services to sponsors

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

EmVenio Clinical Research (formerly Emvenio Research) provides decentralized clinical trial services to pharmaceutical sponsors and CROs through mobile research visits, a network of hospital-embedded Research Centers and neighborhood Community Research Sites, virtual visits, and a Patient Navigator support service. Operations span 90+ countries and are powered by the proprietary ARC(H) Platform (Access, Reach, Community, Human-Centered Research), supporting 800+ studies and 100,000+ patient visits since 2008.

Product overview

EmVenio Clinical Research operates as a unified platform offering three interconnected service lines: Mobile Visits (home and virtual clinical research visits conducted by certified Mobile Research Clinicians), Site Network (Research Centers embedded in hospital campuses and Community Research Sites in local neighborhoods), and Patient Navigator (personalized logistical and financial support). These services are powered by the ARC(H) Platform, which integrates access, reach, community, and human-centered research capabilities across 90+ countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Mobile Visits Home and workplace visits conducted by Mobile Research Clinicians (RNs, NPs, Physicians) that bring clinical trial procedures directly to patients in their homes, workplaces, or preferred locations, removing geographic and logistical barriers.
• Site Network Network of Research Centers embedded in hospital campuses and Community Research Sites embedded in local neighborhoods that bring clinical trials to previously untapped populations, with rapid site activation (under four weeks).
• Patient Navigator Personalized support service providing coordinated travel, lodging, financial reimbursement, and logistical assistance to help patients overcome barriers to clinical trial participation.
• Research Centers Full-service trial capabilities embedded within community-based hospital systems, offering hospital-embedded sites, digitally enabled infrastructure, purpose-built spaces, EHR integration, and hybrid models.
• Community Research Sites Research sites embedded in local neighborhoods to make clinical research accessible and reflective of real-world populations, featuring scalable infrastructure and rapid activation within four weeks.
• Virtual Visits Remote clinical research visits using secure technology and live clinician support, enabling patients to participate from home while maintaining protocol adherence and data quality.
• ARC(H) Platform Integrated platform representing Access, Reach, Community, and Human-Centered Research that powers all EmVenio solutions including mobile visits, community-based teams, and global data capture across 90+ countries.

Quantifiable outcome

• 100,000+ patient visits delivered with industry-leading retention rates
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• SanoficoreStrategic or Co-development Partner · 24 June 2026EmVenio partnered with Sanofi to engage directly with community members at the Juneteenth ATL Parade & Music Festival, expanding awareness of clinical research through approachable, in-person conversations. The partnership demonstrates commitment to inclusive research by meeting people in trusted community spaces.
• CitelineminorStrategic or Co-development Partner · 18 May 2026EmVenio partnered with Citeline to survey 130 leaders from biotech companies, pharmaceutical organizations, and CROs on perspectives regarding community-based research models and their effectiveness in bringing trials closer to patients.
• Prime HealthcarecoreStrategic or Co-development Partner · 6 November 2025EmVenio partnered with Prime Healthcare to open research sites at Prime hospitals across the United States. The partnership improves access to clinical trials for diverse populations in Prime Healthcare's hospital communities. Sites opened at Saint Mary of Nazareth Hospital in Chicago, with additional locations planned at other Prime Healthcare facilities.
• PCM TrialscoreOthers · 1 February 2024PCM Trials acquired EmVenio Research Inc. in February 2024 to strengthen its ability to recruit and retain diverse participant populations through access to EmVenio's site network focused on underserved communities. Subsequently, Clinical Trial Service was also acquired in 2024.
• American Cancer SocietyminorStrategic or Co-development PartnerEmVenio supports the American Cancer Society as part of its corporate responsibility initiative. The partnership reflects shared commitment to improving lives through innovation and compassion, as cancer has touched lives of employees, families, and patients served across both Healthcare and Clinical Research Divisions.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Fortrea: Fortrea (spun out of Labcorp's drug development business) is a global CRO with site management and decentralized trial services; competes with EmVenio across the same enterprise sponsor set with a broader CRO portfolio.
• Syneos Health: Syneos Health is a biopharmaceutical services organization combining a CRO with a clinical site network, offering decentralized trial capabilities that overlap with EmVenio's site network and patient access offerings.
• IQVIA: IQVIA is the largest global CRO with broad decentralized trial capabilities and a global site network; competes with EmVenio on enterprise sponsor RFPs where IQVIA bundles DCT into full-service CRO contracts.
• ICON plc: ICON is a top-tier global CRO offering decentralized and hybrid trial solutions across all phases; competes with EmVenio for large pharma/CRO contracts that require multi-region execution and integrated DCT tooling.

Direct peers

• ObvioHealth: ObvioHealth is a DCT-focused clinical research organization operating its own mobile clinician network and virtual trial platform, comparable to EmVenio's integrated mobile/site/navigator offering for pharma sponsors.
• Science 37: Science 37 is a DCT-native clinical research company that brings trials to patients via home visits, telemedicine, and mobile clinicians — the closest direct analog to EmVenio's mobile/site network model, competing for the same pharma and CRO sponsors.
• Signant Health: Signant Health provides eCOA, ePRO, and patient engagement technology for clinical trials, including decentralized and hybrid designs; comparable to the digital patient-facing and data-capture layer of EmVenio's platform.
• THREAD: THREAD provides a unified DCT platform supporting remote visits, eCOA, and site enablement for decentralized trials; competes with the technology and operational backbone of EmVenio's site network and virtual visit services.
• Medable: Medable is a leading DCT technology platform offering eCOA/ePRO, telehealth, and remote monitoring tools that enable decentralized trial execution; competes with the technology layer underpinning EmVenio's virtual visits and Patient Navigator services.
• Curebase: Curebase runs decentralized and hybrid clinical trials with a software platform and distributed site network, overlapping directly with EmVenio's community-site and home-visit model targeting pharma sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emvenio Research